Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$15.10 USD
+0.15 (1.00%)
Updated Jun 4, 2024 03:36 PM ET
After-Market: $14.59 -0.51 (-3.38%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Assembly Biosciences, Inc. [ASMB]
Reports for Purchase
Showing records 1 - 20 ( 24 total )
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
4Q Recap; ABI-5366 Phase 1a Study Data Expected in 3Q24;Four Programs in the Clinic By YE24; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
3Q Recap; With Gilead Collaboration in Place, Assembly to Have Four Clinical Programs By Year-end 2024; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
Collaboration Agreement With Gilead Provides $100M Cash Infusion And Two New Candidates; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
Entry Inhibitor ABI-6250 Selected As HDV Candidate; Awaiting HSV Program to Enter The Clinic in 1H24; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
2023 International HBV Meeting Presentations Highlight Potential of Assembly''s HBV/HDV Programs; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
2Q Recap; Herpesvirus Program ABI-5366 Enters The Clinic in 1H24; Second Candidate Nomination in 2H23; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
ABI-5366 Shows Potency Against HSV-1 and HSV-2 in First Preclinical Data; Entering the Clinic in 1H24; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
1Q Recap; Herpesvirus Candidate ABI-5366 Expected to Enter the Clinic in 1H24; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
Focus Turns to Programs With Shorter Time to Inflection Points; Core Inhibitor Program Shelved; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
4Q Recap; 4334 Takes Over As Lead Core Inhibitor Program; 3733 On Pause Due to Non-Clinical Toxicity; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
Interim Data on HBV Core Inhibitors Are Early but Highly Encouraging; Next Datasets Expected in 1Q23; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
3Q Recap; 4334 Enters The Clinic Following CTA Approval; 3733 Phase 1b Initial Data by Year-End; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
Assembly Unveils Two New Herpesvirus Programs; Clinical Candidate Identification Expected in 2023; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
2Q Recap; Core Inhibitor Studies Ongoing; Diversifies Portfolio With New Non-HBV Viral Program in 3Q22; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
New Oral Interferon Agonist Program for HBV Unveiled; Third New Program Expected in 3Q22; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
With Vebicorvir Gone and Workforce Right-Sized, Assembly Now All-In on ''3733 and ''4334; PT to $2.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
EASL Presentations Highlight Clinical Potential of Assembly''s Core Inhibitor Programs; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
1Q Recap; Following New HDV Program, New HBV Non- Core Inhibitor Target to Be Unveiled in June; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
4Q Recap; Assembly to Unveil Next Approach to HBV in KOL Event on March 31
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Assembly Biosciences, Inc.
Industry: Medical - Generic Drugs
2022 Pipeline Milestones; Plans to Diversify From the Core Inhibition MoA, and Indeed Beyond HBV
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department